Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 May;39(5):1187–1190. doi: 10.1128/aac.39.5.1187

In vitro activities of various beta-lactam antimicrobial agents against clinical isolates of Escherichia coli and Klebsiella spp. resistant to oxyimino cephalosporins.

B D Jett 1, D J Ritchie 1, R Reichley 1, T C Bailey 1, D F Sahm 1
PMCID: PMC162708  PMID: 7625813

Abstract

Broth microdilution testing was used to study the activity of several beta-lactam antimicrobial agents, including piperacillin-tazobactam and cefepime, against 108 clinically derived Escherichia coli and Klebsiella sp. strains resistant to oxyimino cephalosporins (i.e., putative extended-spectrum beta-lactamase producers). On the basis of the percentage of susceptible strains, imipenem (100%), cefotetan (> or = 92%), and piperacillin-tazobactam (> or = 86%) were the most active agents. Cefepime activity (52 to 64% susceptible) was comparable to that of cefotaxime (40 to 63% susceptible) and aztreonam (20 to 63% susceptible). Among all beta-lactams tested, imipenem and cefotetan demonstrated the highest and most consistent level of activity and were the least affected by challenges with increased sizes of inocula of these resistant organisms.

Full Text

The Full Text of this article is available as a PDF (186.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barradell L. B., Bryson H. M. Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1994 Mar;47(3):471–505. doi: 10.2165/00003495-199447030-00007. [DOI] [PubMed] [Google Scholar]
  2. Bauernfeind A. Perspectives of beta-lactamases inhibitors in therapy of infections caused by Escherichia coli or Klebsiella with plasmidic resistance to third generation cephalosporins. Infection. 1990 Jan-Feb;18(1):48–52. doi: 10.1007/BF01644185. [DOI] [PubMed] [Google Scholar]
  3. Bauernfeind A., Schweighart S., Eberlein E., Jungwirth R. In vitro activity and stability against novel beta-lactamases of investigational beta-lactams (cefepime, cefpirome, flomoxef, SCE2787 and piperacillin plus tazobactam) in comparison with established compounds (cefotaxime, latamoxef and piperacillin). Infection. 1991;19 (Suppl 5):S264–S275. doi: 10.1007/BF01645538. [DOI] [PubMed] [Google Scholar]
  4. Ben Redjeb S., Ben Yaghlane H., Boujnah A., Philippon A., Labia R. Synergy between clavulanic acid and newer beta-lactams on nine clinical isolates of Klebsiella pneumoniae, Escherichia coli and Salmonella typhimurium resistant to third-generation cephalosporins. J Antimicrob Chemother. 1988 Feb;21(2):263–266. doi: 10.1093/jac/21.2.263. [DOI] [PubMed] [Google Scholar]
  5. Bingen E. H., Desjardins P., Arlet G., Bourgeois F., Mariani-Kurkdjian P., Lambert-Zechovsky N. Y., Denamur E., Philippon A., Elion J. Molecular epidemiology of plasmid spread among extended broad-spectrum beta-lactamase-producing Klebsiella pneumoniae isolates in a pediatric hospital. J Clin Microbiol. 1993 Feb;31(2):179–184. doi: 10.1128/jcm.31.2.179-184.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bradford P. A., Cherubin C. E., Idemyor V., Rasmussen B. A., Bush K. Multiply resistant Klebsiella pneumoniae strains from two Chicago hospitals: identification of the extended-spectrum TEM-12 and TEM-10 ceftazidime-hydrolyzing beta-lactamases in a single isolate. Antimicrob Agents Chemother. 1994 Apr;38(4):761–766. doi: 10.1128/aac.38.4.761. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Brun-Buisson C., Legrand P., Philippon A., Montravers F., Ansquer M., Duval J. Transferable enzymatic resistance to third-generation cephalosporins during nosocomial outbreak of multiresistant Klebsiella pneumoniae. Lancet. 1987 Aug 8;2(8554):302–306. doi: 10.1016/s0140-6736(87)90891-9. [DOI] [PubMed] [Google Scholar]
  8. Bryson H. M., Brogden R. N. Piperacillin/tazobactam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs. 1994 Mar;47(3):506–535. doi: 10.2165/00003495-199447030-00008. [DOI] [PubMed] [Google Scholar]
  9. Bush K. Excitement in the beta-lactamase arena. J Antimicrob Chemother. 1989 Dec;24(6):831–836. doi: 10.1093/jac/24.6.831. [DOI] [PubMed] [Google Scholar]
  10. Chanal C. M., Sirot D. L., Petit A., Labia R., Morand A., Sirot J. L., Cluzel R. A. Multiplicity of TEM-derived beta-lactamases from Klebsiella pneumoniae strains isolated at the same hospital and relationships between the responsible plasmids. Antimicrob Agents Chemother. 1989 Nov;33(11):1915–1920. doi: 10.1128/aac.33.11.1915. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Fantin B., Pangon B., Potel G., Caron F., Vallée E., Vallois J. M., Mohler J., Buré A., Philippon A., Carbon C. Activity of sulbactam in combination with ceftriaxone in vitro and in experimental endocarditis caused by Escherichia coli producing SHV-2-like beta-lactamase. Antimicrob Agents Chemother. 1990 Apr;34(4):581–586. doi: 10.1128/aac.34.4.581. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Goldstein E. J., Citron D. M., Cherubin C. E. Comparison of the inoculum effects of members of the family Enterobacteriaceae on cefoxitin and other cephalosporins, beta-lactamase inhibitor combinations, and the penicillin-derived components of these combinations. Antimicrob Agents Chemother. 1991 Mar;35(3):560–566. doi: 10.1128/aac.35.3.560. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Jacoby G. A., Carreras I. Activities of beta-lactam antibiotics against Escherichia coli strains producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother. 1990 May;34(5):858–862. doi: 10.1128/aac.34.5.858. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Jacoby G. A., Medeiros A. A. More extended-spectrum beta-lactamases. Antimicrob Agents Chemother. 1991 Sep;35(9):1697–1704. doi: 10.1128/aac.35.9.1697. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Jaffe A., Chabbert Y. A., Semonin O. Role of porin proteins OmpF and OmpC in the permeation of beta-lactams. Antimicrob Agents Chemother. 1982 Dec;22(6):942–948. doi: 10.1128/aac.22.6.942. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Kempers J., MacLaren D. M. Piperacillin/tazobactam and ticarcillin/clavulanic acid against resistant Enterobacteriaceae. J Antimicrob Chemother. 1990 Oct;26(4):598–599. doi: 10.1093/jac/26.4.598. [DOI] [PubMed] [Google Scholar]
  17. Leleu G., Kitzis M. D., Vallois J. M., Gutmann L., Decazes J. M. Different ratios of the piperacillin-tazobactam combination for treatment of experimental meningitis due to Klebsiella pneumoniae producing the TEM-3 extended-spectrum beta-lactamase. Antimicrob Agents Chemother. 1994 Feb;38(2):195–199. doi: 10.1128/aac.38.2.195. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Livermore D. M. Carbapenemases. J Antimicrob Chemother. 1992 Jun;29(6):609–613. doi: 10.1093/jac/29.6.609. [DOI] [PubMed] [Google Scholar]
  19. Mentec H., Vallois J. M., Bure A., Saleh-Mghir A., Jehl F., Carbon C. Piperacillin, tazobactam, and gentamicin alone or combined in an endocarditis model of infection by a TEM-3-producing strain of Klebsiella pneumoniae or its susceptible variant. Antimicrob Agents Chemother. 1992 Sep;36(9):1883–1889. doi: 10.1128/aac.36.9.1883. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Meyer K. S., Urban C., Eagan J. A., Berger B. J., Rahal J. J. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med. 1993 Sep 1;119(5):353–358. doi: 10.7326/0003-4819-119-5-199309010-00001. [DOI] [PubMed] [Google Scholar]
  21. Neu H. C., Chin N. X., Huang H. B. In vitro activity and beta-lactamase stability of FK-037, a parenteral cephalosporin. Antimicrob Agents Chemother. 1993 Mar;37(3):566–573. doi: 10.1128/aac.37.3.566. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Osano E., Arakawa Y., Wacharotayankun R., Ohta M., Horii T., Ito H., Yoshimura F., Kato N. Molecular characterization of an enterobacterial metallo beta-lactamase found in a clinical isolate of Serratia marcescens that shows imipenem resistance. Antimicrob Agents Chemother. 1994 Jan;38(1):71–78. doi: 10.1128/aac.38.1.71. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Pangon B., Bizet C., Buré A., Pichon F., Philippon A., Regnier B., Gutmann L. In vivo selection of a cephamycin-resistant, porin-deficient mutant of Klebsiella pneumoniae producing a TEM-3 beta-lactamase. J Infect Dis. 1989 May;159(5):1005–1006. doi: 10.1093/infdis/159.5.1005. [DOI] [PubMed] [Google Scholar]
  24. Payne D. J., Amyes S. G. Transferable resistance to extended-spectrum beta-lactams: a major threat or a minor inconvenience? J Antimicrob Chemother. 1991 Mar;27(3):255–261. doi: 10.1093/jac/27.3.255. [DOI] [PubMed] [Google Scholar]
  25. Pearson R. D., Steigbigel R. T., Davis H. T., Chapman S. W. Method of reliable determination of minimal lethal antibiotic concentrations. Antimicrob Agents Chemother. 1980 Nov;18(5):699–708. doi: 10.1128/aac.18.5.699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Philippon A., Labia R., Jacoby G. Extended-spectrum beta-lactamases. Antimicrob Agents Chemother. 1989 Aug;33(8):1131–1136. doi: 10.1128/aac.33.8.1131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Piddock L. J., Griggs D. J. Selection and characterization of cefepime-resistant gram-negative bacteria. J Antimicrob Chemother. 1991 Nov;28(5):669–676. doi: 10.1093/jac/28.5.669. [DOI] [PubMed] [Google Scholar]
  28. Quinn J. P., Miyashiro D., Sahm D., Flamm R., Bush K. Novel plasmid-mediated beta-lactamase (TEM-10) conferring selective resistance to ceftazidime and aztreonam in clinical isolates of Klebsiella pneumoniae. Antimicrob Agents Chemother. 1989 Sep;33(9):1451–1456. doi: 10.1128/aac.33.9.1451. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Rice L. B., Carias L. L., Shlaes D. M. In vivo efficacies of beta-lactam-beta-lactamase inhibitor combinations against a TEM-26-producing strain of Klebsiella pneumoniae. Antimicrob Agents Chemother. 1994 Nov;38(11):2663–2664. doi: 10.1128/aac.38.11.2663. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Rice L. B., Willey S. H., Papanicolaou G. A., Medeiros A. A., Eliopoulos G. M., Moellering R. C., Jr, Jacoby G. A. Outbreak of ceftazidime resistance caused by extended-spectrum beta-lactamases at a Massachusetts chronic-care facility. Antimicrob Agents Chemother. 1990 Nov;34(11):2193–2199. doi: 10.1128/aac.34.11.2193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Rice L. B., Yao J. D., Klimm K., Eliopoulos G. M., Moellering R. C., Jr Efficacy of different beta-lactams against an extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain in the rat intra-abdominal abscess model. Antimicrob Agents Chemother. 1991 Jun;35(6):1243–1244. doi: 10.1128/aac.35.6.1243. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Sanders C. C. Cefepime: the next generation? Clin Infect Dis. 1993 Sep;17(3):369–379. [PubMed] [Google Scholar]
  33. Sanders C. C., Sanders W. E., Jr, Goering R. V., Werner V. Selection of multiple antibiotic resistance by quinolones, beta-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes. Antimicrob Agents Chemother. 1984 Dec;26(6):797–801. doi: 10.1128/aac.26.6.797. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Sanders C. C., Sanders W. E., Jr beta-Lactam resistance in gram-negative bacteria: global trends and clinical impact. Clin Infect Dis. 1992 Nov;15(5):824–839. doi: 10.1093/clind/15.5.824. [DOI] [PubMed] [Google Scholar]
  35. Sirot D., Chanal C., Labia R., Sirot J. Susceptibility of new beta-lactams to the expanded-spectrum beta-lactamase CTX-1. Infection. 1989 Jan-Feb;17(1):28–30. doi: 10.1007/BF01643496. [DOI] [PubMed] [Google Scholar]
  36. Smith C. E., Tillman B. S., Howell A. W., Longfield R. N., Jorgensen J. H. Failure of ceftazidime-amikacin therapy for bacteremia and meningitis due to Klebsiella pneumoniae producing an extended-spectrum beta-lactamase. Antimicrob Agents Chemother. 1990 Jun;34(6):1290–1293. doi: 10.1128/aac.34.6.1290. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Watanabe M., Iyobe S., Inoue M., Mitsuhashi S. Transferable imipenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1991 Jan;35(1):147–151. doi: 10.1128/aac.35.1.147. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES